Volume 28, Issue 1 (Spring 2022)                   IJPCP 2022, 28(1): 138-143 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Soraya S, Seddigh R, Hadi F, Faramarzi M. Chemical; The New Trend of addiction in Iran. IJPCP 2022; 28 (1) :138-143
URL: http://ijpcp.iums.ac.ir/article-1-3550-en.html
1- Department of Psychiatry, Faculty of Medicine, Research Center of Addiction and Risky Behavior, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Psychiatry, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Psychiatry, Faculty of Medicine, Research Center of Addiction and Risky Behavior, Iran University of Medical Sciences, Tehran, Iran. , m.faramarzi89@yahoo.com
Full-Text [PDF 1020 kb]   (1186 Downloads)     |   Abstract (HTML)  (3581 Views)
Full-Text:   (1104 Views)
Dear Editor
Synthetic cannabinoids (SC) are a heterogeneous group of substances with a high affinity for cannabinoid receptors. Unlike Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids are incredibly potent, highly productive, have more affinity for the cannabinoid receptor type 1 (CB1), and cannabinoid receptor type 2 (CB2), and are designed to accelerate the effects of tetrahydrocannabinol. Also, there is experimental evidence that SCs act on non-cannabinoid receptors, such as the 5-HT2B receptor or dopaminergic receptors [1, 2].
In 1984, following the attempts to treat multiple sclerosis (MS), John Hoffman developed a cannabis-like substance called K2, or chemical, which was a synthetic cannabinoid.
In Iran, Merasuite or Bonzai, accompanied by salvia, are used to produce the Chemical [2, 3].
In other countries, the chemical )in the language of the streets ‘Bonzai’( known as ‘1-naphthalene of methanol’ with its other name JWH-18 group, is a drug belonging to the group of synthetic cannabinoids, and its main psychoactive substance is Δ-9 tetra-hydro cannabinol (THC) with agonists effects on the CB1 and CB2 [2, 4 ,5, 6]. The sale of these drugs over the Internet and in special markets started from the beginning of 2004 with brands, such as Spice, K2, Black Mambo, Aroma, Dream, Bonzai, Maui Wowie, Nice Nice, etc. [1, 7].
Salvia (salvinorin A) is one of the most potent psychoactive substances and has a much stronger effect than its natural counterparts. Thus, it is much more harmful as well. These industrial samples bind to receptors in the brain, lungs, kidneys, and liver and affect the consumer’s body; thus, they have various psychological and physical effects. One of the most important effects is short-term memory impairment, severe hallucinations, dizziness, and visual disturbances [2, 8, 9, 10, 11]. Other manifestations are respiratory problems, high blood pressure, tachycardia, chest pain, muscle strain, acute renal failure, anxiety, irritability, psychosis, and also the idea of ​​suicide and cognitive impairment. Chronic use of synthetic cannabinoids has been associated with severe psychological and medical conditions and even death. The visual hallucinogenic effects of Salvia are very strong and similar to the effects of lysergic acid diethylamide (LSD). Some users have reported mystical and spiritual experiences [2, 12 ,13 ,1415]. 
Synthetic cannabinoids have become increasingly popular, especially among teenagers and young adults, despite their harms and hallucinogenic effects, and unfortunately are available at a low price. Although its consumption is increasing, most consumers are not familiar with the side effects; therefore, it seems necessary to introduce the physical and psychological effects to doctors, healthcare workers, families, and the general population, including teenagers. 

Ethical Considerations
Compliance with ethical guidelines

All ethical principles are considered in this article. 

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors contributions
Research, draft writing: Mohammad Faramarzi; editing and finalization of the text: Shiva Soraya; project management: All authors.

Conflicts of interest
The authors declare no conflicts of interest.

Acknowledgements
The Addiction Clinic of Iran Psychiatry Center, which helped us in completing this article, is thanked and appreciated.




References
  1. Benser S, McGregor IS, Guinea R. Labs make new, dangerous synthetic cannabinoid drugs faster than we can ban them. California: University of California; 2015. [Link]
  2. Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. «Zombie» outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. The New England Journal of Medicine. 2017;  376(3):235-42.  [PMID]
  3. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006; 58(3):389-462. [DOI:10.1124/pr.58.3.2] [PMID] [PMCID]
  4. Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O. Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Foresic science international. 2014; 243:23-9. [DOI:10.1016/j.forsciint.2014.02.022] [PMID]
  5. Ergül DF, Ekemen S, Yelken BB. Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series. Turkish Journal of Anaesthesiology and Reanimation. 2015; 43(5):347-51. [PMID]
  6. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. British Journal of Pharmacology. 2010; 160(3):585-93. [PMID] [PMCID]
  7. Lopresti AL. Salvia (Sage): A review of its potential cognitive-enhancing and protective effects. Drugs in R&D. 2017; 17(1):53-64. [DOI:10.1007/s40268-016-0157-5] [PMID] [PMCID]
  8. Mahendran R, Lim HA, Tan JY, Chua SM, Winslow M. Salvia divinorum: An overview of the usage, misuse, and addiction processes. Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists. 2016; 8(1):23-31. [DOI:10.1111/appy.12225] [PMID]
  9. Zjawiony JK, Machado AS, Menegatti R, Ghedini PC, Costa EA, Pedrino GR, et al. Cutting-edge search for safer opioid pain relief: Retrospective review of salvinorin A and Its analogs. Frontiers in Psychiatry. 2019; 10:157. [Link]
  10. Amato L, Minozzi S, Mitrova Z, Parmelli E, Saulle R, Cruciani F, et al. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy (Italian)]. Epidemiologia e Prevenzione. 2017; 41(5-6):279-93. [PMID]
  11. Tournebize J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: Update 2015. Substance Abuse. 2017; 38(3):344-66.  [PMID]
  12. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015; 313(24):2456-73. [PMID]
  13. John ME, Thomas-Rozea C, Hahn D. Bath salts abuse leading to new-onset psychosis and potential for violence. Clinical Schizophrenia & Related Psychoses. 2017; 11(2):120-4. [PMID]
  14. Penders TM, Gestring RE, Vilensky DA. Excited delirium following use of synthetic cathinones (bath salts). General Hospital Psychiatry. 2012; 34(6):647-50. [PMID]
  15. Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. Pharmacokinetics and pharmacodynamics of salvinorin a and salvia divinorum: Clinical and forensic aspects. Pharmaceuticals (Basel). 2021; 14(2):116. [DOI:10.3390/ph14020116] [PMID]
Type of Study: Letter to the editor | Subject: Psychiatry and Psychology
Received: 2021/08/9 | Accepted: 2021/11/29 | Published: 2022/04/20

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Psychiatry and Clinical Psychology

Designed & Developed by : Yektaweb